Obesity Drug Treatments – Patient Pays
Obesity drug treatments can be prescribed for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity.
In the USA, a four-week course of Wegovy has a list price of $1,349 a month. Mounjaro has a list price of $974 for four weekly doses. In the UK, pharmacies will charge patients with private insurance or those paying out of their own pockets between £199 and £299 ($251-$377) for a month’s supply of Novo Nordisk’s weight-loss drug Wegovy.
The cost of administering these drugs is not currently covered by (a) any national health service nor (b) any private medical insurance – so the cost must be borne by the patient.